Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

CEBP Focus: Patient Navigation in Cancer Care

Randomized Controlled Trial of Patient Navigation for Newly Diagnosed Cancer Patients: Effects on Quality of Life

Samantha Hendren, Jennifer J. Griggs, Ronald Epstein, Sharon Humiston, Pascal Jean-Pierre, Paul Winters, Mechelle Sanders, Starlene Loader and Kevin Fiscella
Samantha Hendren
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer J. Griggs
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Epstein
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon Humiston
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Jean-Pierre
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Winters
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mechelle Sanders
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Starlene Loader
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Fiscella
1Departments of Family Medicine and Community & Preventive Medicine, University of Rochester School of Medicine & Dentistry; 2Department of Surgery, 3Department of Medicine, Division of Medical Oncology, University of Michigan School of Medicine; 4Department of Family Medicine, University of Rochester School of Medicine & Dentistry; 5Department of Pediatrics, Children's Mercy Hospitals and Clinics; 6Department of Pediatrics, University of Miami Miller School of Medicine; and 7Department of Family Medicine, Highland Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-12-0537 Published October 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Patient navigation is a promising intervention to ameliorate cancer health disparities. This study objective was to measure patient navigation effects on cancer-specific quality of life (QOL) among patients with newly diagnosed cancer.

Methods: A randomized controlled trial of patient navigation was conducted in Rochester, NY. Patients with breast cancer and colorectal cancer were randomly assigned to receive a patient navigation intervention or usual care. QOL was measured at baseline and four subsequent time points, using the validated Functional Assessment of Cancer Therapy (FACT-B, FACT-C) instruments.

Results: Among 319 randomized patients (165 patient navigation, 154 control), median age was 57 years and 32.5% were from minority race/ethnicity groups. Patient navigation and control groups were comparable on baseline factors, except home ownership versus renting (more home ownership among controls, P = 0.05) and race (more whites among controls, P = 0.05). Total and subscale FACT scores did not differ between groups when analyzed as a change from baseline to 3 months, or at various time points. The emotional well-being subscale change from baseline approached significance (better change among patient navigation group, P = 0.05). Time trends of QOL measures did not differ significantly between groups. Adjustment for baseline patient factors did not reveal a benefit of patient navigation on QOL.

Conclusions: In this randomized trial of patient navigation, there was no statistically significant effect on disease-specific QOL.

Impact: These results suggest that patient navigation may not affect QOL during cancer treatment, that social/medical support are adequate in this study's setting, or that the trial failed to target patients likely to experience QOL benefit from patient navigation. Cancer Epidemiol Biomarkers Prev; 21(10); 1682–90. ©2012 AACR.

Introduction

In the United States, poor and minority patients have poorer cancer survival than majority populations. This multifactorial phenomenon is likely due to a lack of access to timely and high-quality medical care, communication barriers, and lack of social support, and other resources (1). Pioneered in the 1990′s in Harlem by cancer surgeon Harold P. Freeman, patient navigation is an intervention to provide support to disadvantaged cancer screening and diagnosed cancer patients, to address barriers to and delays in care (2, 3). In an effort to rigorously test the effects of patient navigation on cancer health disparities, the National Cancer Institute and the American Cancer Society sponsored a nationwide group of trials to test the effectiveness of patient navigation, including effects on timeliness of care, patient satisfaction, and disease-specific quality of life (4).

Patients with cancer experience decreased quality of life (QOL) during and after treatment, and multiple studies of cancer survivors and of noncancer populations have shown that low socioeconomic status is associated with poorer quality of life, including domains of psychologic functioning, social functioning, and physical functioning (5–8). Therefore, QOL is important to consider among cancer patients' outcomes, including of patient navigation interventions. There is a theoretical basis for the hypothesis that patient navigation might improve QOL in patients with cancer, in addition to their timeliness of care (9). Numerous studies have shown that increased social support improves QOL in patients with cancer, mainly in the setting of cancer support groups (10–13). Because a primary focus of the patient navigation role is providing social support, similar QOL effects might be seen to support groups. There are also some nonrandomized data suggesting that patient navigation may be associated with improved QOL (14). These studies support the hypothesis that patient navigation might improve' QOL in patients with cancer and/or decrease disparities in QOL.

In this context, the current randomized controlled trial tests the effect of an intensive patient navigation intervention on disease-specific QOL, among newly diagnosed patients with breast and colorectal cancer.

Materials and Methods

Research setting

This randomized trial was part of the National Cancer Institute-sponsored Patient Navigation Research Program (15). It focused on the impact of patient navigation on patients with newly diagnosed breast and colorectal cancer; details of the study protocol have been previously described.(16) The trial was approved by the Institutional Review Board of the University of Rochester (Rochester, NY), and informed consent was provided by each participating patient. Patients were recruited from 13 oncology and primary care practices serving disadvantaged patients in Rochester, New York and the surrounding suburbs. Most patients were referred by 3 large hospital-based oncology practices.

Patient eligibility was defined as adult patients with definitively diagnosed breast cancer or colorectal cancer treated at a participating practice. Patients were excluded if they were institutionalized, had dementia, or had prior cancer (except for nonmelanoma skin cancer). During the study, 928 patients were referred for possible enrollment; 337 declined to participate, 145 were ineligible, and 122 were unable to be contacted. The remaining 324 were enrolled in the study, of which 319 were diagnosed cancer patients who were administered the FACT quality of life questionnaire (the remaining patients were patients with a positive cancer screening test but not diagnosed cancer; these were excluded from the current analysis because the FACT instruments are not relevant to these patients).

Intervention

Before randomization, participating patients completed research-assistant–administered questionnaires, and chart reviews were also conducted to abstract disease and treatment information. Race-ethnicity classifications were obtained directly from patients. After the initial interview, eligible patients were randomized to intervention or usual care by a study statistician using computer-generated numbers. Randomization was stratified by the site of enrollment, in blocks of 4 patients. Assignments were placed in sealed envelopes and opened by the research assistant following confirmation of eligibility.

Patient navigation (including multiple in-person and telephone interactions) was provided by trained, nonmedical personnel housed in the research offices of the Department of Family Medicine, University of Rochester. An intensive training process completed by navigators and their supervision and evaluation has been previously described (16). The navigators interacted with patients via in-person and telephone meetings, and used a semi-structured interview procedure to determine barriers that each cancer patient may be facing. Barriers had standardized definitions, and included financial, social, logistical, language, medical and mental health comorbidities, attitudes such as fear and mistrust, and communication barriers. These were addressed by the patient navigators in various ways, including appointment scheduling, reminders, arranging transportation, accompanying patients to appointments when requested, and helping patients to make list of questions and take notes to improve communication.

Outcomes

The objective of the present study was assessment of the cancer-specific quality of life (QOL), which was the prespecified secondary outcome for this randomized, controlled trial. The validated Functional Assessment of Cancer Treatment (FACT-G) general instrument, as well as breast- and colorectal cancer-specific modules (FACT-B and FACT-C, respectively), were self-administered at baseline and at 3, 6, 9, and 12 months (17). For Spanish-speaking patients, the FACT was administered in a (translated and back-translated) Spanish version. These scales yield a total score and 5 subscale scores: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Additional Concerns (cancer type-specific questions). There are 36 questions, scored on a 5-point Likert scale (0 = not at all, 4 = very much). The FACT scales have been rigorously validated and used in numerous cancer trials and studies (9, 17–21). Text of questions is included in Tables 3 and 4.

Statistical analysis

Patient baseline characteristics were compared between randomized groups to assess whether the groups were balanced on key characteristics after randomization, using χ-square tests and Fisher exact tests as appropriate. The numerical data of the FACT instruments were compared with t tests. The primary analysis involved comparing the change in QOL scores from baseline to 3 months between randomized groups, with and without stratification by cancer type (breast vs. colorectal cancer). This was calculated by subtracting the FACT (total and subscale) scores at baseline from the scores at 3 months. The potential benefits of patient navigation would be expected to be seen most prominently during this time frame because newly diagnosed patients would be expected to have greatest difficulty “navigating” the complex cancer treatment system. Over time, patients would be expected to develop more familiarity with the system and require less logistical assistance. However, because cancer patients' QOL scores fluctuate with treatment and over time, additional analyses were conducted to compare QOL scores between randomized groups at the later time points, as well (22). The scores on subscales were also compared between groups at the various time points, and QOL trends over time were also compared between randomized groups. Finally, a repeated-measures linear regression model was used to test for association between navigation and QOL while adjusting for differences in baseline characteristics. SAS 9.2 for Windows was used for analysis.

Results

Three hundred nineteen patients with newly diagnosed cancer were enrolled in the study, 270 with breast cancer and 49 with colorectal cancer. Of these, 165 were randomized to patient navigation and 154 to the control group; 299 patients answered the FACT questionnaire at both baseline and 3 months. Characteristics of the patients are shown in Table 1. The median age was 57 years and 32.5% were from minority race/ethnicity groups. The 2 groups were generally well matched; however, they differed marginally on home ownership status (more renting and less home ownership among patients randomized to navigation, P = 0.05) and race (P = 0.05), with more minority patients in the navigated group.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

The primary analysis compared the change in QOL scores (total and subscale) from baseline to 3 months (Table 2), for all patients and for patients with breast and colorectal cancer separately. These results show no statistically significant differences, although the Emotional Well-Being subscale scores were marginally significant, with the trend favoring the navigation group (P = 0.05).

View this table:
  • View inline
  • View popup
Table 2.

FACT quality of life scores: difference between baseline and 3-month time points

Unadjusted FACT total and subscale scores at the 3, 6, 9, and 12 month time points were compared between randomized navigation versus control groups (3-month timepoint shown in Tables 3 and 4). There was no significant difference in scores between groups at any time points. Analysis of the time trends of FACT total and subscale scores also did not show any significant differences, for total score or subscale scores.

View this table:
  • View inline
  • View popup
Table 3.

FACT-B scores for navigated and control patients at 3 months (n = 259)

View this table:
  • View inline
  • View popup
Table 4.

FACT-C scores for navigated and control patients at 3 months (n = 46)

Finally, analyses were conducted to test for interactions between patient factors and QOL scores based on greater hypothesized benefit for more socially disadvantaged patients. The a priori analysis plan was to test the following factors for interactions: race/ethnicity, income, insurance, and language. These analyses revealed significant interactions between QOL scores over time and the baseline patient factors of gender and housing status. Because of these interactions and the possibility that the navigated patients represented a more disadvantaged group (Table 1), we then conducted a multivariable model to test the association between patient navigation and overall QOL scores, adjusting for age, gender, race/ethnicity, income and housing status. This analysis also failed to show improved QOL score associated with patient navigation over time.

Discussion

This study revealed that patient navigation did not affect disease-specific QOL scores among patients with cancer undergoing primary treatment. There was no difference in the overall score or among subscales potentially more sensitive to patient navigation, such as social or emotional well-being (although the association between patient navigation and emotional well-being was marginally statistically significant). These results are particularly striking, given that this study used an intensive intervention that included multiple in-person plus telephone supports. Furthermore, QOL was measured using well-validated instruments with demonstrated sensitivity to change (18, 21).

Multiple studies have documented that a cancer diagnosis—and cancer treatment—have negative effects on the QOL (20, 23, 24). For patients with breast and colorectal cancer, effects on physical, emotional, and functional QOL are seen both during active treatment, and in some cases during survivorship (20). At the outset of this trial of patient navigation, to address cancer disparities, we hypothesized that particular aspects of QOL would be modifiable with patient navigation. For example, the physical effects of pain and nausea during treatment might be better controlled if the navigator helped patients to communicate these concerns more effectively to providers; or worry and uncertainty might be reduced through social support and improved culturally sensitive information. In our study, QOL was relatively stable over time in both the navigated and control groups, but failed to show differences between these groups.

Why was patient navigation not associated with overall improved QOL? There are both study-specific and theoretical explanations for the failure of this study to support our hypothesis. First, this study targeted cancer centers and other practices that serve socioeconomically disadvantaged patients with cancer, but these centers also serve higher-income patients with cancer. As such, participating patients included both patients of lower and higher participants, some of whom may not benefit from the help of a patient navigator. However, we observed no interaction between patient navigation and disadvantage.

Second, the majority of participants were recruited from two multidisciplinary cancer centers, in which the problem of cancer health disparities has become recognized. Patients in these centers have had increasing access to help from social workers and volunteer cancer survivors, who may have contaminated the study by providing similar supports to patients in the control group. Also, the majority of study patients were patients with breast cancer, who have been shown in prior studies to use support group services more frequently than other cancer patients (25). As such, our findings might not be generalizable to other cancers in which the social support offered by navigation might make a greater difference (because it is otherwise lacking). Another possible source of contamination was our research assistants, who administered questionnaires to both control and patient navigation-randomized patients quarterly. While they were trained to limit their interactions to collection of survey data, their inherently empathetic and engaging personalities may have been an unintended source of social support for participants, some of whom reported these interactions as supportive.

In addition to these study-specific reasons, patient navigation may have difficulty achieving an improvement in QOL due to a threshold effect of social support on distress. Mallinckrodt and colleagues published a study in which social support had an effect on patients with breast cancer' distress only among the lowest quartile of social support, supporting a threshold effect (26). In support of this hypothesis, we observed an impact on emotional well-being that was marginally significant. Also, QOL in the active phase of cancer treatment may simply be dominated by the relatively immutable (to a navigator or other support person) factors of treatment side effects and the variable process of learning to live with a cancer diagnosis. Finally, it is reasonable to speculate that cancer care providers have become increasingly aware of the importance of patient-centered outcomes over time, and that their care is in general more supportive of patients' quality of life.

The implications of this study for cancer quality improvement and disparities reduction are that patient navigation may not have an appreciable effect on QOL, at least in treatment settings similar to the setting of this study. QOL may be improved via providers' effective symptom management, use of minimally invasive therapies when possible, and fitness programs (27), but perhaps not via patient navigation programs (at least for patients with breast cancer). The big picture is that while certain cancer treatments such as surgery, chemotherapy, and hormonal therapy have negative effects on QOL, particularly in the short-term, the most significant factor in long-term quality of life for most patients with cancer is freedom from recurrence (28). As such, the thoughtful counsel of cancer providers in balancing long- and short-term QOL remains of greatest importance.

While this randomized trial has several methodological strengths compared with prior studies, it has the limitations of being a single-center study that may not be generalizable to other cancer treatment settings or cancer types. Also, the inclusion of patients of higher socioeconomic status may have limited the ability of this study to show an effect of patient navigation on outcomes although we did not observe effects for more disadvantaged participants

In conclusion, an intensive patient navigation intervention had no effect on disease-specific QOL, among patients with breast and colorectal cancer undergoing primary cancer treatment. These results may reflect this trial's patient selection, the baseline care in this research setting, or simply that the QOL during cancer treatment is insensitive to social and instrumental support interventions. Future studies will focus on other possible effects of patient navigation for patients undergoing cancer treatment and confirm the potential effect on patient emotional well-being.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: S. Hendren, R. Epstein, S. Humiston, K. Fiscella

Development of methodology: S. Hendren, J.J. Griggs, S. Humiston, K. Fiscella

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Loader, K. Fiscella

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Hendren, R. Epstein, S. Humiston, P. Winters, K. Fiscella

Writing, review, and/or revision of the manuscript: S. Hendren, J.J. Griggs, R. Epstein, S. Humiston, P. Jean-Pierre, P. Winters, M. Sanders, K. Fiscella

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P. Winters, M. Sanders, S. Loader, K. Fiscella

Study supervision: S. Loader, K. Fiscella

Grant Support

This research was supported by Grant U01 CA116924-01 (Principal Investigator K. Fiscella) from the National Cancer Institute.

  • Received April 30, 2012.
  • Revision received July 16, 2012.
  • Accepted July 16, 2012.
  • ©2012 American Association for Cancer Research.

References

  1. 1.↵
    1. Mandelblatt JS,
    2. Yabroff KR,
    3. Kerner JF
    . Equitable access to cancer services: A review of barriers to quality care. Cancer 1999;86:2378–90.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Freeman HP
    . Patient navigation: a community based strategy to reduce cancer disparities. J Urban Health 2006;83:139–41.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Freeman HP,
    2. Muth BJ,
    3. Kerner JF
    . Expanding access to cancer screening and clinical follow-up among the medically underserved. Cancer Practice 1995;3:19–30.
    OpenUrlPubMed
  4. 4.↵
    1. Wells KJ,
    2. Battaglia TA,
    3. Dudley DJ,
    4. Garcia R,
    5. Greene A,
    6. Calhoun E,
    7. et al.
    Patient navigation: state of the art or is it science? Cancer 2008;113:1999–2010.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Short PF,
    2. Mallonee EL
    . Income disparities in the quality of life of cancer survivors. Med Care 2006;44:16–23.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Bowen DJ,
    2. Alfano CM,
    3. McGregor BA,
    4. Kuniyuki A,
    5. Bernstein L,
    6. Meeske K,
    7. et al.
    Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. Breast Cancer Res Treat 2007;106:85–95.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Hao Y,
    2. Landrine H,
    3. Smith T,
    4. Kaw C,
    5. Corral I,
    6. Stein K
    . Residential segregation and disparities in health-related quality of life among Black and White cancer survivors. Health Psychol 2011;30:137–44.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Audureau E,
    2. Rican S,
    3. Coste J
    . Worsening trends and increasing disparities in health-related quality of life: evidence from two French population-based cross-sectional surveys, 1995–2003. Qual Life Res. 2012 Feb 2. [Epub ahead of print].
  9. 9.↵
    1. Fiscella K,
    2. Ransom S,
    3. Jean-Pierre P,
    4. Cella D,
    5. Stein K,
    6. Bauer JE,
    7. et al.
    Patient-reported outcome measures suitable to assessment of patient navigation. Cancer 2000;117:3603–17.
    OpenUrl
  10. 10.↵
    1. Davison KP,
    2. Pennebaker JW,
    3. Dickerson SS
    . Who talks? The social psychology of illness support groups. Am Psychol 2000;55:205–17.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Winzelberg AJ,
    2. Classen C,
    3. Alpers GW,
    4. Roberts H,
    5. Koopman C,
    6. Adams RE,
    7. et al.
    Evaluation of an internet support group for women with primary breast cancer. Cancer 2003;97:1164–73.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Goodwin PJ,
    2. Leszcz M,
    3. Ennis M,
    4. Koopmans J,
    5. Vincent L,
    6. Guther H,
    7. et al.
    The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345:1719–26.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Tehrani AM,
    2. Farajzadegan Z,
    3. Rajabi FM,
    4. Zamani AR
    . Belonging to a peer support group enhance the quality of life and adherence rate in patients affected by breast cancer: A non-randomized controlled clinical trial. J Res Med Sci 2011;16:658–65.
    OpenUrlPubMed
  14. 14.↵
    1. Fillion L,
    2. de Serres M,
    3. Cook S,
    4. Goupil RL,
    5. Bairati I,
    6. Doll R
    . Professional patient navigation in head and neck cancer. Semin Oncol Nurs 2009;25:212–21.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Freund KM,
    2. Battaglia TA,
    3. Calhoun E,
    4. Dudley DJ,
    5. Fiscella K,
    6. Paskett E,
    7. et al.
    National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer 2008;113:3391–9.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hendren S,
    2. Griggs JJ,
    3. Epstein RM,
    4. Humiston S,
    5. Rousseau S,
    6. Jean-Pierre P,
    7. et al.
    Study protocol: a randomized controlled trial of patient navigation-activation to reduce cancer health disparities. BMC Cancer 2010;10:551.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Cella DF,
    2. Tulsky DS,
    3. Gray G,
    4. Sarafian B,
    5. Linn E,
    6. Bonomi A,
    7. et al.
    The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Brady MJ,
    2. Cella DF,
    3. Mo F,
    4. Bonomi AE,
    5. Tulsky DS,
    6. Lloyd SR,
    7. et al.
    Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974–86.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Cella D
    . Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales, version 4. Evanston, IL: Center on Outcomes Research and Education, Evanston Northwestern Healthcare and Northwestern University; 1997.
  20. 20.↵
    1. Montazeri A
    . Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ward WL,
    2. Hahn EA,
    3. Mo F,
    4. Hernandez L,
    5. Tulsky DS,
    6. Cella D
    . Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181–95.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Montazeri A,
    2. Vahdaninia M,
    3. Harirchi I,
    4. Ebrahimi M,
    5. Khaleghi F,
    6. Jarvandi S
    . Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer 2008;8:330.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Janz NK,
    2. Mujahid M,
    3. Chung LK,
    4. Lantz PM,
    5. Hawley ST,
    6. Morrow M,
    7. et al.
    Symptom experience and quality of life of women following breast cancer treatment. J Womens Health (Larchmt) 2007;16:1348–61.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Hendren SK,
    2. O'Connor BI,
    3. Liu M,
    4. Asano T,
    5. Cohen Z,
    6. Swallow CJ,
    7. et al.
    Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212–23.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Stevinson C,
    2. Lydon A,
    3. Amir Z
    . Cancer support group participation in the United Kingdom: a national survey. Support Care Cancer 2005;19:675–83.
    OpenUrl
  26. 26.↵
    1. Mallinckrodt B,
    2. Armer JM,
    3. Heppner PP
    . A threshold model of social support, adjustment, and distress after breast cancer treatment. J Couns Psychol 2012;59:150–60.
    OpenUrlPubMed
  27. 27.↵
    1. Morey MC,
    2. Snyder DC,
    3. Sloane R,
    4. Cohen HJ,
    5. Peterson B,
    6. Hartman TJ,
    7. et al.
    Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. JAMA 2009;301:1883–91.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Arndt V,
    2. Merx H,
    3. Stegmaier C,
    4. Ziegler H,
    5. Brenner H
    . Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. Eur J Cancer 2006;42:1848–57.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 21 (10)
October 2012
Volume 21, Issue 10
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Randomized Controlled Trial of Patient Navigation for Newly Diagnosed Cancer Patients: Effects on Quality of Life
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Randomized Controlled Trial of Patient Navigation for Newly Diagnosed Cancer Patients: Effects on Quality of Life
Samantha Hendren, Jennifer J. Griggs, Ronald Epstein, Sharon Humiston, Pascal Jean-Pierre, Paul Winters, Mechelle Sanders, Starlene Loader and Kevin Fiscella
Cancer Epidemiol Biomarkers Prev October 1 2012 (21) (10) 1682-1690; DOI: 10.1158/1055-9965.EPI-12-0537

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Randomized Controlled Trial of Patient Navigation for Newly Diagnosed Cancer Patients: Effects on Quality of Life
Samantha Hendren, Jennifer J. Griggs, Ronald Epstein, Sharon Humiston, Pascal Jean-Pierre, Paul Winters, Mechelle Sanders, Starlene Loader and Kevin Fiscella
Cancer Epidemiol Biomarkers Prev October 1 2012 (21) (10) 1682-1690; DOI: 10.1158/1055-9965.EPI-12-0537
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Patient Navigation RCT for Cancer Treatment
  • The Ohio Patient Navigation Research Program
  • Patient Navigation Reduces Delays in Breast Cancer Diagnosis
Show more CEBP Focus: Patient Navigation in Cancer Care
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement